Verastem | VSTM - Cost Of Sales


Verastem reported $2.89M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alaunos Therapeutics USD 0 18K Sep/2024
AstraZeneca USD -204M 3.48B Mar/2026
Curis USD 314K 9.96M Dec/2025
Cytokinetics USD 160K 104.24M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Laboratory Of America USD 2.6B 4.2M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
TG Therapeutics USD 33.51M 4.63M Mar/2026
Verastem USD 2.89M 2.88M Dec/2025